IVD Technology
Magazine
IVDT Article Index
Originally published September, 1997
Business & Marketing
A directory of market reports
Knowledge is power, they say. So here's a bundle of power in the form of key marketing information for IVD manufacturers.Each month, the editors of IVD Technology receive dozens of phone calls from people inquiring about the status of the market for particular types of in vitro diagnostics. To help readers keep up with the growth of technologies and market opportunities in the industry, IVDT has compiled a list of current market reports that analyze the industry and its future. A brief summary of each report's contents, gathered from the publisher's catalogs, brochures, or the report's table of contents, is provided, as well as length, price, and date of publication. In addition, a directory of the companies publishing these reports is provided. Contact the companies directly concerning purchase of reports or for additional information contained in the reports or the company's other research.
Changes in Diagnostic Practice
Financial Times
156 pp, $488, May 1996
The clinical diagnostics industry comprises the in vitro and electromedical diagnostic markets. These two markets are converging as automation and close-to-patient testing increase. According to this report, no more than 20 companies will soon account for 90% of sales in the world's IVD and electromedical markets. This report projects market potential by product type to the year 2000 and analyzes the future of the industry, its changing structure and market drivers, and successful and failed technologies. It includes profiles of 26 leading diagnostics companies and discusses the health-care, medical device, and IVD regulatory systems of the key global markets.
The Market for Rapid In Vitro Diagnostic Tests
FIND/SVP
300+ pp, $2950, February 1997
Worldwide, the market for rapid IVD tests grew 9.6% in 1996 to $623 million. Sales in the United States reached $259 million, primed by point-of-care testing and shaped by lab-licensing regulatory changes, managed-care cost-cutting measures, and drug legislation. Rapid-IVD-test marketers face competition from automated labs and managed care; the future of the rapid-test market lies in acceptance at the level of hospitals and independent laboratories.
Medical Testing Chemicals
The Freedonia Group, Inc.
204 pp, $3200, February 1996
Demand for medical testing chemicals will expand more than 8% per year (or 3.7% when adjusted for inflation) to $5.1 billion in the year 2000. The expanding need for pretreatment diagnostics will keep the demand for medical chemical testing concentrated in routine clinical chemistry and x-ray substances. The fastest gains will occur among immunology and hematology chemicals, based on advances in monoclonal antibodies that will enhance the reliability of AIDS testing and lead to new tests for previously hard-to-detect cancers, allergies, and autoimmune disorders. The report includes discussions of the national and international markets and the industry structure.
European Diagnostic Products: Competitive Benchmarking
Frost & Sullivan
489 pp, $1950, May 1997
This study examines 50 companies involved in the development, production, and marketing of diagnostic products and services in Europe, and forecasts trends to 2003. Market sectors analyzed include IVDs, electromedical diagnostic equipment, patient monitoring, and diagnostic enhancement reagents.
European In Vitro Cancer Diagnostic Markets
Frost & Sullivan
231 pp, $3900, August 1996
In vitro cancer diagnostic markets in Europe are highly specialized and extremely competitive. Profitability is declining because of increased competition. This trend is expected to continue, because testing sites across Europe have consolidated to create large laboratories that reduce expenses through economies of scale. As a result, manufacturers must supply automated machinery that can process broad testing parameters with minimum expenditure. This report examines major market and technology trends, revenues and growth rates, and market leaders' strategies for success.
European Non-Isotopic Immunoassay System Markets
Frost & Sullivan
271 pp, $3900, March 1996
This report analyzes the European non-isotopic immunoassay system market in terms of revenues, pricing, and industry trends from 1992 to 2002. Four major system product markets are addressed: manual nonisotopic immunoassay systems, semiautomated systems, automated batch systems, and automated random-access systems, which offer increased accuracy, high-volume throughput, and significantly reduced operator involvement.
European Rapid Microbiology Product Markets
Frost & Sullivan
353 pp, $3950, November 1996
The many segments of the rapid microbiology market do not combine to form a single, coherent industry, and the suppliers are diverse. Competitors bring different backgrounds to the market and range from large, well-rounded multinationals to small companies specializing in one area. This report examines the industry, provides forecasts for the market to 2002, provides revenue, trend, and competitive information for each market segment, and describes current and emerging strategies.
European Research Biochemical Markets
Frost & Sullivan
355 pp, $3950, June 1997
Recent advances in biotechnology have caused the use of biochemical research reagents to spread to laboratories involved in disciplines as disparate as forensic science and archaeology. Biochemical research reagent companies will be serving rapidly growing markets, and the release of new products will be necessary if they are to remain competitive and profitable. This report is divided into product categories examining the molecular biology, cell biology, immunology, protein chemistry, and analytical reagents markets in Europe. Key participants' current marketing, sales, and development strategies are examined, and industry leaders are profiled.
European Spectrometer and Spectrophotometer Markets
Frost & Sullivan
396 pp, $3950, September 1996
The spectrometers and spectrophotometers market has experienced widespread merger and acquisition activity and continued consolidation. The market is expected to follow a price-led recovery from the recession through sales of high-end and application-specific instruments and analyzers. Innovative uses of Fourier transform analyzers are currently of great interest to manufacturers. This study provides revenue, trend, and competitive information for each European market segment and describes the current and emerging strategies of market leaders.
U.S. Biotechnology and Pharmaceutical Instrumentation Markets
Frost & Sullivan
471 pp, $2495, March 1996
Demand for biotechnology and pharmaceutical instrumentation has grown significantly in the past 15 years. In 1995, manufacturer revenues swelled to $560 million in the United States. By 2001, biotechnology and pharmaceutical instrumentation revenues are projected to reach $1 billion. This report analyzes market trends, particularly toward the miniaturization of instrumentation technology, and examines market leaders' strategies for success.
U.S. DNA Probe Markets
Frost & Sullivan
313 pp, $3295, December 1996
DNA probes have historically been used in research to locate and identify particular genes of interest. Major technological advances in recent years have launched this research tool into the clinical laboratory. Using small amounts of DNA, probe technology holds promise as a testing method for more than 4000 genetic diseases. For the next five years, however, infectious disease diagnostics are projected to be the most active market segment. This report analyzes market and technology trends and examines current and emerging competitive strategies.
U.S. Markets for In Vitro Sensor Technologies, 19952000
Medical Data International, Inc.
178 pp, $2850, August 1996
Driven by a continued emphasis on point-of-care testing, the market for in vitro sensor-based clinical diagnostic products is expected to experience strong growth, reaching $1.2 billion in sales by 2000--an average annual increase of 20.1%. Sensors are expected to be important in every major segment of the clinical diagnostics market, including clinical chemistry, immunodiagnostics, cellular analysis, and microbiology. The report covers electrochemical sensors, optical sensors, noninvasive optical spectroscopy, electrooptical sensors, mass sensors and microanalytical technology, and the role of sensor technology in clinical testing. It also includes sections on new trends and emerging technologies, market analyses and sales forecasts, and profiles of 23 companies.
U.S. Rapid Microbiology Test Markets
Frost & Sullivan
460 pp, $2995, May 1997
Point-of-care testing allows earlier, accurate diagnosis and treatment, eliminating costly delays. Manufacturers are just beginning to tap into this promising area for clinical microbial test development. This study presents analyses of and forecasts for the market to 2003 and describes current marketing, sales, and development strategies of key market participants and industry leaders.
U.S. Reference Laboratory Testing Markets
Frost & Sullivan
368 pp, $2995, January 1997
The reference laboratory testing industry is under considerable cost pressures. Current trends make it difficult for laboratories to earn profits. Most labs are gambling that they can sacrifice profits for market share or target only profitable niches. This report provides an overview of the clinical chemistry, hematology, immunoassay, and chromatography testing markets. It then examines the current and emerging strategies of the market leaders.
World Biosensor Markets
Frost & Sullivan
250 pp, $2450, March 1997
The world biosensors market is on the verge of significant expansion. This report provides analysis of the biosensor industry and explores key competitive issues, including research and development into new technologies, expansion into new markets, and increasingly stringent international laws. Analysis and forecasts are provided to 2003 for medical, environmental, industrial, and military biosensor market segments.
World Clinical Laboratory Analytical Instrument Markets
Frost & Sullivan
517 pp, $2995, January 1996
For clinical laboratories, increased automation and instrument consolidation eliminates instrument and labor costs by reducing the number of instruments used and operators required. This report provides an overview of the world market and provides complete revenue, trend, and competitive information for the chemistry analyzer, hematology analyzer, immunoassay analyzer, electrolyte analyzer, blood gas analyzer, bilirubinometer, and osmometer markets.
AIDS Diagnostics and Therapeutics Markets
Theta Reports
100+ pp, $995, June 1997
The home market for AIDS testing expanded in mid-1996, and the clinical reference laboratory testing segment is expected to increase significantly. The automation of test processes, incorporation of gp120 testing capabilities, and development of less-expensive DNA probe testing procedures to determine viral load will affect the market for AIDS diagnostics. The report analyzes clinical, competitive, demographic, and technological trends affecting the current and future expansion of the AIDS diagnostics and therapeutics markets. Revenues and growth rates are included for the market segments, with projections to 2002.
Biotechnology Laboratory Products Market
Theta Reports
100+ pp, $1295, June 1997
The market for laboratory products currently exceeds $2 billion. Bioseparations, cell handling, cell culturing, sequencing/synthesizing, and life-science consumables are assessed. The report includes discussion of liquid chromatography, electrophoresis, tissue culture incubators, fermentors, capillary electrophoresis, biosensors, disposable glassware, restriction enzymes, PCR, separation resins, columns, detectors, and nucleic acid and amino acid synthesizers and sequencers.
Blood Gas and Electrolyte Instruments Markets
Theta Reports
116 pp, $995, January 1997
The U.S. market for blood gas and electrolyte analyzers is projected to grow from $314 million in 1995 to $343 million in 1998. By 1998, worldwide sales will exceed $1 billion. The report examines market trends and new developments in dedicated electrolyte analyzers and blood gas instruments marketed to hospital labs and to clinics and doctors' offices performing medium- to high-volume automated clinical chemistry testing. Sales volume and market size are projected by segment to the year 2000.
Cancer Diagnostics and Therapeutic Markets
Theta Reports
161 pp, $995, August 1996
Competition is increasing in the cancer diagnostics and therapeutic products market. Among diagnostics, tumor markers are expected to grow 10% annually, led by growth in the sales of PSA tests. Sales by genetic testing services are expected to reach $1 billion by the next decade. The report provides an overview of the market, offers insight into new cancer drugs and diagnostic techniques and systems, and provides market forecasts and company profiles.
Cytologic Diagnostics Markets
Theta Reports
100+ pp, $995, March 1997
The cytometry systems market totals more than $500 million worldwide and is expected to reach $685 million by the year 2000. The market is expected to grow 5 to 8% annually, with the market for reagents growing faster than that for instrumentation. The report examines the cytometry systems market, including research and clinical segments, through 2000.
Diagnostic Market and Technology Trends--Worldwide
Theta Reports
100+ pp, $1295, April 1997
By the year 2000, hospital consolidations and the related emphasis on preventive medicine, testing guidelines, and optimized treatment scheduling will create an increasing need for more timely delivery of diagnostic test information. The result will be greater use of point-of-care testing and an increase in the number of sophisticated diagnostic tests allowing for customized patient therapeutics. The report examines the evolution of IVD technologies in major world markets through 2000. Key categories include immunoassays, general chemistries, hematology/coagulation, microbiology, DNA probe assays, and cytology.
DNA Diagnostics and Gene Therapy Markets
Theta Reports
120+ pp, $995, March 1997
This report examines the maturing diagnostic market for nonamplified assays for pathogenic bacteria, where combination tests for chlamydia and gonorrhea dominate. Technologies based on biochips and oligonucleotide arrays have received financial support from venture capitalists and government funding agencies. PCR and other target amplification technologies applied to high-sensitivity assays for bacteria and viruses are entering the market, as is genetic screening. The report tracks the progress, prospects, and players in this growing market.
Laboratory Disposables Markets
Theta Reports
100+ pp, $995, September 1997
The report forecasts total and market segment revenues through 2002 for disposable products that are used for automated and nonstandard testing in general laboratory, hematology, immunology, microbiology, pathology, and toxicology procedures. The report also provides a series of company profiles that describe the top competitors in the lab disposables market, and a competitive analysis evaluates consolidation and restructuring strategies.
Point-of-Care Testing in Hospital Markets
Theta Reports
100+ pp, $995, March 1997
This report considers the advantages and disadvantages of point-of-care testing in hospital settings. It discusses the internal and external influences, facilitators, and impediments to hospital adoption of POC testing methods. Market size, shares, and growth are provided for glucose monitoring, critical care, coagulation, cardiac risk, and other product areas, including urinalysis and drug-of-abuse testing. Company information is provided for market leaders and niche companies, and a directory of companies active in the market is included.
Point-of-Care Testing: Physician's/Home
Theta Reports
145 pp, $995, December 1996
This report analyzes consumer self-testing and physician-office markets for point-of-care testing. The leading products covered are blood glucose test strips, pregnancy and ovulation tests, and blood pressure monitors. Fecal occult blood testing, cholesterol tests, and HIV tests are also covered. The home-test market is projected to grow 14% per year over the next five years. By 1999, several new test categories will be available in the home segment, with noninvasive glucose monitors expected to be the largest.
Separations: Chromatography and Electrophoresis
Theta Reports
90 pp, $995, July 1996
The report examines the size and growth of the $1.3-billion separations market in biotechnology, biopharmaceutical, biomedical, research, and industrial applications. HPLC systems, columns, and detectors; low-pressure LC, chromatography supplies and reagents; electrophoresis; and star capillary electrophoresis are covered. The report projects growth rates to 2001, gives current market shares of major competitors, and profiles 10 companies. Among other results, the report concludes that computerization and software will be key to market success, and that HPLC will offer the largest market segment through 2001.
U.S. Biotechnology Research Reagent Market
Theta Reports
97 pp, $995, October 1996
The biotechnology research reagents and kits market is divided into three segments: molecular biology, immunochemistry, and peptides. The report projects sales by user, application, and manufacturer for each of these segments through 2001. Only the laboratory research market is covered. The report predicts continued double-digit market growth through 2001.
Market-Study Publishers
Financial Times
14 East 60th St., Ste. 1206, Penthouse
New York, NY 10022
212/888-3469
FIND/SVP
625 Avenue of the Americas, Dept. FNF
New York, NY 10011
800/346-3787
The Freedonia Group, Inc.
3570 Warrensville Center Rd., Ste. 201
Cleveland, OH 44122-5226
216/921-6800
Frost & Sullivan
2525 Charleston Rd.
Mountain View, CA 94043
415/961-9000
Medical Data International, Inc.
2 Park Plaza, Ste. 1200
Irvine, CA 92614
800/826-5759
Theta Reports
1775 Broadway, Ste. 511
New York, NY 10019
212/262-8230
